Comparison of Oxcarbazepine Versus Carbamazepine in the Management of Trigeminal Neuralgia
Key facts
- Who runs it
- Jinnah Postgraduate Medical Centre
- Where
- Pakistan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 4
- People taking part
- 122 people, planned
- Started
- 21 Sept 2024
- Ended
- 21 Mar 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Oxcarbazepine
- Carbamazepine
- Record updated
- 4 March 2025
Who can take part
- Age
- 25 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Patients of either gender (male or female)
- Patients of age 25-80 years
- Patients presenting with trigeminal neuralgia of any frequency and severity (according to operational definition) for six months
- Patients not already receiving carbamazepine or oxcarbazepine for the management of trigeminal neuralgia
Who cannot take part
- Patients who have undergone any surgical procedure for the treatment of trigeminal neuralgia
- Patients not already receiving carbamazepine or oxcarbazepine for the management of trigeminal neuralgia
- Patients with renal and hepatic issue such as chronic renal failure and chronic liver disease
- Patients with seizures
- Patients who are intolerant to and allergic to both treatment drugs (oxcarbazepine and carbamazepine)
- Pregnant and Iactating mothers
- Patients who are not willing to participate in the study
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Trigeminal neuralgia is a debilitating neurological condition, affecting quality of life in most affected patients. Carbamazepine has traditionally been used for the management of this condition, but it has a moderate effectiveness and a poor side-effect profile. Oxcarbazepine is more tolerable, and has a more favorable side-effect profile. This study aims to compare the effectiveness of oxcarbazepine and carbamazepine in the management of this condition, for improved prescription practices in the future.
The 2 groups in the trial
- Oxcarbazepine (Group A)Treatment being tested
Starting dose of oxcarbazepine 150 mg BD, titrated up if no pain relief
Treatment: Oxcarbazepine
- Carbamazepine (Group B)Existing treatment, for comparison
Starting dose of carbamazepine 100 mg BD, titrated up if no relief
Treatment: Carbamazepine
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Comparison of Oxcarbazepine Versus Carbamazepine in the Management of Trigeminal Neuralgia in Patients Presenting in Outpatient Department of Neurology in Jinnah Postgraduate Medical Centre
- Record updated
- 4 March 2025